Literature DB >> 30561578

Herpes Zoster Rates Continue to Decline in People Living With Human Immunodeficiency Virus but Remain Higher Than Rates Reported in the General US Population.

Laura Gilbert1, Xun Wang2,3, Robert Deiss2,3,4, Jason Okulicz2,5, Ryan Maves2,4, Christina Schofield2,6, Tomas Ferguson2,7, Timothy Whitman2,8, Karl Kronmann2,9, Brian Agan2,3, Anuradha Ganesan2,3,8.   

Abstract

In the antiretroviral therapy era, herpes zoster incidence continued to decline in people living with HIV (PLWH). However, at 0.9 cases/100 person-years, rates in PLWH are substantially higher than the general US population; emphasizing the needs for studies of the subunit vaccine in PLWH.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; declining incidence; herpes zoster

Year:  2019        PMID： 30561578      PMCID： PMC6579953          DOI： 10.1093/cid/ciy1041

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.

Authors:  Constance A Benson; Janet W Andersen; Bernard J C Macatangay; Robbie B Mailliard; Charles R Rinaldo; Sarah Read; Dawn R Bozzolo; Lynette Purdue; Cheryl Jennings; Michael C Keefer; Marshall Glesby; Pablo Tebas; Amy Falk Russell; Jason Martin; Paula Annunziato; Zoran Popmihajlov; Jeffrey L Lennox
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

2.  The incidence of herpes zoster in a United States administrative database.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier; Patricia Saddier; Alexander A Nikas
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

3.  Herpes zoster among persons living with HIV in the current antiretroviral therapy era.

Authors:  Leah J Blank; Michael J Polydefkis; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

4.  Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.

Authors:  Sophie Grabar; Pierre Tattevin; Hana Selinger-Leneman; Arnaud de La Blanchardiere; Pierre de Truchis; Christian Rabaud; David Rey; Vincent Daneluzzi; Samuel Ferret; Anne-Sophie Lascaux; Thomas Hanslik; Dominique Costagliola; Odile Launay
Journal:  Clin Infect Dis       Date:  2015-01-18       Impact factor: 9.079

Review 5.  Varicella zoster virus infection.

Authors:  Anne A Gershon; Judith Breuer; Jeffrey I Cohen; Randall J Cohrs; Michael D Gershon; Don Gilden; Charles Grose; Sophie Hambleton; Peter G E Kennedy; Michael N Oxman; Jane F Seward; Koichi Yamanishi
Journal:  Nat Rev Dis Primers       Date:  2015-07-02       Impact factor: 52.329

6.  Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care.

Authors:  Amy C Weintrob; Greg A Grandits; Brian K Agan; Anuradha Ganesan; Michael L Landrum; Nancy F Crum-Cianflone; Erica N Johnson; Claudia E Ordóñez; Glenn W Wortmann; Vincent C Marconi
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

7.  Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Joel E Gallant; Khalil G Ghanem; Patricia Emmanuel; Barry S Zingman; Michael A Horberg
Journal:  Clin Infect Dis       Date:  2014-01       Impact factor: 9.079

8.  Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Authors:  Elchonon M Berkowitz; Graeme Moyle; Hans-Jürgen Stellbrink; Dirk Schürmann; Stephen Kegg; Matthias Stoll; Mohamed El Idrissi; Lidia Oostvogels; Thomas C Heineman
Journal:  J Infect Dis       Date:  2014-11-03       Impact factor: 5.226

9.  Incidence of herpes zoster in patients with altered immune function.

Authors:  S-Y Chen; J A Suaya; Q Li; C M Galindo; D Misurski; S Burstin; M J Levin
Journal:  Infection       Date:  2013-11-10       Impact factor: 3.553

10.  Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.

Authors:  Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-26       Impact factor: 17.586
View more
  3 in total

1.  Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.

Authors:  Jennifer Beecker; Curtis Cooper; Mark G Kirchhof; Anton L Pozniak; Juergen K Rockstroh; Kim A Papp; Jan P Dutz; Melinda J Gooderham; Robert Gniadecki; Chih-Ho Hong; Charles W Lynde; Catherine Maari; Yves Poulin; Ronald B Vender; Sharon L Walmsley
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-21

2.  Seropositivity, Risks, and Morbidity From Varicella-Zoster Virus Infections in an Adult PWH Cohort From 2000-2020.

Authors:  Jason Zou; Hartmut B Krentz; Raynell Lang; Brenda Beckthold; Kevin Fonseca; M John Gill
Journal:  Open Forum Infect Dis       Date:  2022-08-09       Impact factor: 4.423

Review 3.  Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.

Authors:  Alemnew F Dagnew; Peter Vink; Mamadou Drame; David O Willer; Bruno Salaun; Anne E Schuind
Journal:  Hum Vaccin Immunother       Date:  2021-06-30       Impact factor: 3.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.